Summary of Use during Lactation

No information is available on the clinical use of sacituzumab govitecan during breastfeeding. Because sacituzumab is a large protein molecule, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Govitecan is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for at least 1 month after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]

2.

Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]

Substance Name

Sacituzumab Govitecan

CAS Registry Number

1491917-83-9

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Antibodies, Monoclonal

Immunoconjugates

Topoisomerase I Inhibitors